Drug intelligence / Profile preview

MUC1-KLH conjugate plus QS-21

Development stage: Phase 1
Lead developer: National Cancer Institute
Modality: Recombinant Proteins and Enzymes, Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

MUC1-KLH conjugate plus QS-21 is a therapeutic cancer vaccine composed of a synthetic peptide derived from the human tumor-associated antigen mucin 1 (MUC1), chemically linked to keyhole limpet hemocyanin (KLH) as a carrier protein and administered with the immunological adjuvant QS-21. The combination is designed to stimulate an immune response against tumor cells expressing the MUC1 antigen. KLH enhances immunogenicity of the peptide, while QS-21 acts as an adjuvant to further boost antibody production and cellular immune responses. The primary indication has been in high-risk breast cancer and other epithelial cancers such as ovarian and prostate cancer. The developer is the National Cancer Institute[2][3][4][5].

Other names: MUC1-KLH conjugate vaccineMUC-1-KLH conjugate vaccineMUC 1-KLH conjugate vaccineMUC1-keyhole limpet hemocyanin (KLH) conjugate plus QS-21

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on MUC1-KLH conjugate plus QS-21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MUC1-KLH conjugate plus QS-21.

Explore the full profile